Europe - GIT Verlag

More documents

Recommendations

Info

8 MEdIcAL tEcHnoLoGY Hospital Post Europe 04/08 Marked by change and bathed in tradition, the distinct and rich cultural heritage of Barcelona once again set the stage for EuroPCR 2008. The 18 th edition of the internationally renowned cardiology course took place in the middle of May. EuroPCR is the official congress of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) … with the collaboration of the European Society of Cardiology (ESC), the European Association of Cardio- Thoracic Surgeons (ARCTS), the Transcatheter Valve Symposium (TVS) as well as the endorsement of numerous interventional cardiology worldwide. Over 10,000 participants attended this year’s meeting, representing over 80 countries – an extremely satisfactory figure according to the organizers, the French company Europa Organisation. Abbott Vascular “Express the Truth to Gain the Trust” Successful 18 th Edition of EuroPCR in Barcelona These Are Some of the Vendors Who Showcased Their Recent Highlights at EuroPCR: this exhibitor presented long-term data from the sPIrIt III trial, a pivotal trial studying the XIEncE v Everolimus Eluting coronary stent system. the results demonstrated that this stent continues to deliver clinically superior benefits for patients compared to the tAXus paclitaxeleluting system. In the trial of more than 1,000 patients, XIEncE v demonstrated a 45 % reduction in the risk of major adverse cardiac events (MAcE) and a 32 % reduction in the risk of target vessel failure (cardiac events related to the treated vessel) at two years as compared to tAXus. “not only did XIEncE v clearly differentiate itself from the tAXus stent in the first year after treatment, it has now demonstrated even more positive effects at two years in the sPIrIt III trial,” said dr. stone, columbia university Medical center and chairman, cardiovascular research Foundation, new York. “As measured by clinically significant reductions in target vessel failure and MAcE, XIEncE v demonstrated an even greater improvement in patient outcomes compared to tAXus at two years than at one year, driven by numerically lower rates of heart attacks and lower observed rates of re-intervention of the target lesion. We also saw encouraging trends for lower observed rates of late and very late stent thrombosis in XIEncE v-treated patients, especially in those who discontinued dual antiplatelet therapy.” www.abbottvascular.com www.abbott.com Agfa HealthCare For the first time, this company displayed its solution for convergence of images and clinical data through integrated lesion follow-up. the solution will be part of IMPAX cardiovascular for integrated data and image management in cardiology. the software, which will be available later this year, allows the clinician to focus on the monitoring of the stenosis in a time-longitudinal view, with all relevant data and images in one view, rather than being required to upload the separate studies, as is currently the standard. “the solution is an integral part of the company‘s drive towards the convergence of images and clinical data,” says dr. ciprian Albu, Medical director of Agfa Healthcare for cardiology. “[We are] the first to achieve a full integration of the image follow-up as part of the overall clinical follow-up of any procedures. this turns the post procedure monitoring of coronary lesions into a more time efficient process, reducing the need to sift through unrelated data.” the new feature will be incorporated into Agfa Healthcare‘s IMPAX cardiovascular, a solution with integrated multi-modality and multi-lingual cardiovascular information management providing a consolidated view of all cardiology and radiology images within a single review station. IMPAX cardiovascular is vendor-neutral and delivers innovative features, including tightly integrated structured reporting, legacy equipment image management, and secure global access to diagnostic data. www.agfa.com Edwards Lifesciences Key figures from EuroPCR included: 617 faculty speakers, 34 Scientific societies, 14,000 m² of exhibition space, and 145 collaborating companies. this vendor announced the launch of a next-generation transfemoral delivery system for the sapien transcatheter heart valve. the retroFlex II delivery system retains many of the features of the retroFlex delivery system, and adds a tapered nose cone that facilitates the passage of the valve delivery catheter over the curve of the aortic arch and through the patient‘s native, diseased aortic heart valve. the new system is designed to enhance ease-of-use and improve access during the transcatheter aortic valve replacement procedure. the first procedures with the new transfemoral delivery system were performed by John Webb, director of the cath lab and cardiac intervention at st. Paul‘s Hospital in vancouver, British columbia. His multidisciplinary team has performed more than 150 transcatheter aortic valve replacement procedures, including more than 25 utilizing the retroFlex II delivery system. “the retroFlex II delivery system is a big step forward. It is designed to give the physician maximum control when delivering and implanting the transcatheter aortic valve, making it easier to get to and then cross the patient‘s native valve“, said Webb. www.edwards.com OrbusNeich orbusneich announced that multiple clinical data presentations in a symposium at EuroPcr 2008 support the use of the company’s Genous Bio-engineered r stent, the world’s first pro-healing stent, as a safe alternative to drug-eluting stents. Presented by robbert de Winter, M.d., of the Academic Medical center in Amsterdam, data from the trIAs Hr (high risk) pilot study show similar target vessel failure (tvF) rates at 12-month follow-up for orbusneich’s Genous Bio-engineered r stent and Boston scientific’s taxus stent in high risk of restenosis patients. In the patients treated with taxus, there were four out-of-hospital thrombotic events, while there were no reported events in the Genous group. “Interventional cardiologists need better stent technologies,” said de Winter, principal investigator of the trIAs Hr Pilot study. “A pro-healing approach with the Genous stent is a viable one. We look forward to obtaining further data on the stent’s performance in our large, multi-center trIAs trials that compare Genous to both drug-eluting and bare metal stents.” In addition, de Winter presented interim follow-up data from patient subsets of e-healing, a monitored, multi-center, worldwide (outside the united states) prospective registry with 5,000 enrolled patients. the data based on the real-world use of the Genous Bio-engineered r stent show: good clinical outcomes at six and 12 months, a low target lesion revascularization (tLr) rate of 4.7 % at 12 months in patients with diabetes and a low incidence of stent thrombosis. the protocol for orbusneich’s e-healing registry recommends that patients receive one month of clopidogrel treatment after the procedure. clinical follow-up takes place at 30 days, six months and 12 months. the primary outcome of the registry is tvF at 12 months. www.orbusneich.com 3mensio Medical Imaging the dutch software development company receives cE Mark class IIa for 3surgery vascular Imaging workstation. university Hospital utrecht’s department of vascular surgery in the netherlands has been working with the “3surgery” workstation within the “the next dimension“ project since 2006. the project was initiated by Prof. dr. Frans Moll to validate measurements on length, diameter, as well as volumetric data generated by this workstation. dr. Joost van Herwaarden, co worker of Prof. dr. Moll who performed this extensive clinical validation, says: “We have used our extensive patient database in utrecht to validate both volumetric and linear measurements performed with the 3surgery system and we conclude that the tools are accurate and above all easy to use in our busy daily practice.“ Imaging has become crucial in the process of diagnosis and pre operative procedures. new promising techniques like Endo vascular Aneurysm repair (EvAr) rely completely on an accurate diagnosis and measurements using solely 2d and 3d images from the radiology department. 3surgery vascular imaging software provides these accurate tools for the pre and post operative planning of your procedures on any Pc. Prof. dr. Frans Moll adds: “After the validation we will use the 3surgery imaging workstation to address our clinical needs to measure volumetric parameters. this will have an effect on both pre-operative decisions as well as treatment of patients already having an endovascular prosthesis.” www.3surgery.com
Hospital Post Europe 04/08 The 18 th edition of the internationally renowned cardiology course – EuroPCR 2008 – took place mid May. Under construction since 1882: the Temple Expiatori de la Sagrada Família, often simply called the Sagrada Família, is one of the most popular attractions in Spain. EuroPCR is a unique course aiming to contribute to the advancement of education and information on existing and new technologies in percutaneous interventions in the fields of coronary, peripheral, valve and non-coronary cardiac disease, cardiothoracic and vascular surgery and imaging. During the four day course, the programme focused on two key messages: “what is best for my patient” and “together we achieve more”. This patient-centred approach consolidated innovative technology and established learning pro cesses. Participants had the chance to learn and share experiences with some of the world’s leading cardiology experts during more than 100 hours of live transmission from 17 international centres. This year’s event – in addition to allowing professionals to share experiences – included the launch of an important initiative to provide training and aid in the field of cardiovascular disease in sub-Saharan Africa – a joint collaboration of EuroPCR, the Government of Monaco and EAPCI. This important initiative was announced during the opening ceremony of the Course and is endorsed by H.S.H. the Prince Albert II of Monaco. According to Marc Doncieux, President of Europa Organisation, “we are extremely proud to have been able to welcome His Serene Highness to our annual course and believe that his support of the cardiovascular training initiative will be vital in ensuring the success of the project”. Other highlights of this year’s event included the EuroPCR awards ceremony and the presentation of the Alicia Foundation, created by the Generalitat de Catalunya and Caixa Manresa dedicated to food and science that was presented by the highly acclaimed chef Ferran Adriá and leading cardiologists Valentin Fuster and Carlos Ruiz. Regarding the future, Marc Doncieux confirmed “the 19 th edition of EuroPCR will return to the Barcelona International Convention Centre in 2009 and, following a very productive meeting held with the key city hoteliers this week, and with the continued support of the local authorities we are hopeful that we will be able to host this important event in this beautiful city”. Christina Keil MEdIcAL tEcHnoLoGY 9 What’s one way to dramatically impact Critical Care ? Euroanaesthesia 2008 May 31 - June 3 Copenhagen, Denmark Bella Center Hall C2, booth 038 Reduce length of stay by up to 3 days EuroPCR 2009 takes place from 19 to 22 May – again at the International Convention Centre (CCIB-Forum) in Barcelona www.europcronline.com Dräger’s non-invasive ventilation (NIV) technology holds the key. By offering NIV across our complete line of ventilators and integrating SyncPlus ® advanced leakage compensation technology, we can support your efforts to both avoid intubation whenever possible, and facilitate rapid weaning and extubation. As a result, the use of NIV for acute respiratory failure has the potential of reducing hospital morbidity, shortening patient length of stay and reducing the cost of care; while at the same time improving patient comfort. Yet this is just one aspect of our integrated CareArea Solutions, to impact your entire patient care process. To discover how all our innovative solutions can impact your care process, visit www.draeger.com *Ram FSF et al, The Cochrane Library 2005, Issue 4 Dräger Medical: Emergency Care > Perioperative Care > Critical Care > Perinatal Care > Home Care *
Page 1 and 2: 76961 4/2008 Dedicated Drug-Device
Page 3 and 4: Hospital Post Europe 04/08 For dise
Page 5 and 6: Hospital Post Europe 04/08 What a c
Page 7: Hospital Post Europe 04/08 Welfare
Page 11 and 12: Hospital Post Europe 04/08 Mölnlyc
Page 13 and 14: Hospital Post Europe 04/08 MEdIcAL
Page 15 and 16: Hospital Post Europe 04/08 “Contr
Page 17 and 18: Hospital Post Europe 04/08 250 part
Page 19 and 20: Hospital Post Europe 04/08 The seco
Page 21 and 22: Hospital Post Europe 04/08 Kantonss
Page 23 and 24: Hospital Post Europe 04/08 LABorAto
Page 25 and 26: Hospital Post Europe 04/08 Pronosti
Page 27 and 28: Hospital Post Europe 04/08 Through

Europe - GIT Verlag

Create successful ePaper yourself

Delete template?

Save as template?